Ten years ago, Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so rapidly that she was ineligible for a bone marrow transplant to treat it. Her family came to CHOP in the hopes that Dr. Stephan Grupp, a pioneer in the field of cellular immunotherapy, could provide the miracle they were looking for.
Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL).
A study led by researchers at UCLA and CHLA has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.
Children and young adults who receive CAR T-cell therapy for the most common childhood cancer – acute lymphoblastic leukemia – suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds.
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia.
Family looks to the ‘bright side’ by creating a charity to support pediatric cancer research and providing UChicago Medicine Comer Children’s Hospital with $500,000 gift.
Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers at Albert Einstein College of Medicine, Children’s Hospital at Montefiore (CHAM), and Rutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop protective interventions that can prevent permanent harm.
Researchers have found that genetically defined subpopulations of leukemia cells present at diagnosis have distinct characteristics that lead to relapse.
A study combining low-dose chemotherapy with a monoclonal antibody is effective for older patients with Philadelphia chromosome-negative ALL.
A St. Jude Children’s Research Hospital study lowered the rate of relapse for patients with acute lymphoblastic leukemia.
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology and Director of the Cancer Immunotherapy Program at Children’s Hospital of Philadelphia, has been elected into the National Academy of Medicine (NAM), effective Oct. 1, 2019.